UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 248

Sortiert nach

Therapeutic approaches for spinal muscular atrophy (SMA)

Gene therapy, 2017-09, Vol.24 (9), p.514-519

2017

Volltextzugriff (PDF)

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Lancet neurology, 2021-10, Vol.20 (10), p.832-841

2021

Volltextzugriff (PDF)

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy

Neurology, 2012-05, Vol.78 (22), p.1714

2012

Volltextzugriff (PDF)

Congenital myopathies – Clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom

Neuromuscular disorders : NMD, 2013-03, Vol.23 (3), p.195-205

2013

Volltextzugriff (PDF)

A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs

Neuromuscular disorders : NMD, 2021-04, Vol.31 (4), p.300-309

2021

Volltextzugriff (PDF)

Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats

Molecules (Basel, Switzerland), 2015-09, Vol.20 (9), p.16758-16769

2015

Volltextzugriff (PDF)

Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain

Peptides (New York, N.Y. : 1980), 2012-04, Vol.34 (2), p.412-418

2012

Volltextzugriff (PDF)

The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment

Life sciences (1973), 2012-01, Vol.90 (1), p.66-70

2012

Volltextzugriff (PDF)

SEPN1-related myopathies: clinical course in a large cohort of patients

Neurology, 2011-06, Vol.76 (24), p.2073

2011

Volltextzugriff (PDF)

Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand

Life sciences (1973), 2012-06, Vol.90 (25-26), p.957-961

2012

Volltextzugriff (PDF)

Six minute walk test in type III spinal muscular atrophy: A 12 month longitudinal study

Neuromuscular disorders : NMD, 2013-08, Vol.23 (8), p.624-628

2013

Volltextzugriff (PDF)

Effects of intraplantar Nocistatin and (±)-J 113397 injections on nociceptive behavior in a rat model of inflammation

Pharmacology, biochemistry and behavior, 2012-01, Vol.100 (3), p.639-644

2012

Volltextzugriff (PDF)

Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain

Life sciences (1973), 2009-07, Vol.85 (5), p.206-210

2009

Volltextzugriff (PDF)

SMA REACH UK: Relationship between the Revised Hammersmith Scale (RHS) and Revised Upper Limb Module (RULM) in a UK cohort of patients with SMA type 2 and 3

Neuromuscular disorders : NMD, 2017-03, Vol.27, p.S43-S43

2017

Volltextzugriff (PDF)

Design and Synthesis of New Bifunctional Sigma‑1 Selective Ligands with Antioxidant Activity

Journal of medicinal chemistry, 2013-03, Vol.56 (6), p.2447-2455

2013

Volltextzugriff (PDF)

Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients

Neuromuscular disorders : NMD, 2014-04, Vol.24 (4), p.347-352

2014

Volltextzugriff (PDF)

Evaluation of N-substitution in 6,7-benzomorphan compounds

Bioorganic & medicinal chemistry, 2010-07, Vol.18 (14), p.4975-4982

2010

Volltextzugriff (PDF)

Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study

Neuromuscular disorders : NMD, 2013-08, Vol.23 (8), p.624-628

2013

Volltextzugriff (PDF)

Microvascular defects secondary to SMN deficiency in spinal muscular atrophy

Neuromuscular disorders : NMD, 2017-03, Vol.27, p.S29-S29

2017

Volltextzugriff (PDF)

Dysregulation of microRNAs in spinal muscular atrophy and the response to antisense oligonucleotide therapy

Neuromuscular disorders : NMD, 2015-10, Vol.25, p.S194-S194

2015

Volltextzugriff (PDF)

Microvascular abnormality in spinal muscular atrophy and its response to antisense oligonucleotide therapy

Neuromuscular disorders : NMD, 2015-10, Vol.25, p.S193-S193

2015

Volltextzugriff (PDF)

Revised Hammersmith scale for spinal muscular atrophy: Inter and intra-rater reliability and content validity from a patient perspective

Neuromuscular disorders : NMD, 2015-10, Vol.25, p.S195-S195

2015

Volltextzugriff (PDF)

Exploring the microvascular abnormalities in a cohort of paediatric patients with spinal muscular atrophy

Neuromuscular disorders : NMD, 2016-10, Vol.26, p.S105-S105

2016

Volltextzugriff (PDF)

Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia

Peptides (New York, N.Y. : 1980), 2007-07, Vol.28 (7), p.1441-1446

2007

Volltextzugriff (PDF)

Modulation of cytoplasmic dynein and tubulin modification as potential therapeutic targets in SMA-LED

Neuromuscular disorders : NMD, 2017-03, Vol.27, p.S1-S1

2017

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(226)

Publikationsform

Artikel
(247)
Webseiten
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Therapeutic approaches for spinal muscular atrophy (SMA)

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy

Congenital myopathies – Clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom

A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs

Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats

Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain

The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment

SEPN1-related myopathies: clinical course in a large cohort of patients

Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand

Six minute walk test in type III spinal muscular atrophy: A 12 month longitudinal study

Effects of intraplantar Nocistatin and (±)-J 113397 injections on nociceptive behavior in a rat model of inflammation

Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain

SMA REACH UK: Relationship between the Revised Hammersmith Scale (RHS) and Revised Upper Limb Module (RULM) in a UK cohort of patients with SMA type 2 and 3

Design and Synthesis of New Bifunctional Sigma‑1 Selective Ligands with Antioxidant Activity

Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients

Evaluation of N-substitution in 6,7-benzomorphan compounds

Six minute walk test in type III spinal muscular atrophy: A 12month longitudinal study

Microvascular defects secondary to SMN deficiency in spinal muscular atrophy

Dysregulation of microRNAs in spinal muscular atrophy and the response to antisense oligonucleotide therapy

Microvascular abnormality in spinal muscular atrophy and its response to antisense oligonucleotide therapy

Revised Hammersmith scale for spinal muscular atrophy: Inter and intra-rater reliability and content validity from a patient perspective

Exploring the microvascular abnormalities in a cohort of paediatric patients with spinal muscular atrophy

Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia

Modulation of cytoplasmic dynein and tubulin modification as potential therapeutic targets in SMA-LED

Suchergebnisse filtern